Kevin Bilyard has worked in the pharmaceutical and biotechnology industries since completing his PhD in chemistry at University College London in 1981. He joined GlaxoSmithKline before moving to AstraZeneca and he has subsequently held a variety of executive roles in development stage biotech companies. The most recent of these was CEO and director of Immodulon Therapeutics, an immuno-oncology company, until 2021. Kevin is a co-founder of Nugerontix where he has been a non-executive director since the company's formation. He has broad experience of pharmaceutical product development and product strategy and a successful track record of bringing new products through the development process.

Roger Corder is Founder and Chief Executive Officer of Nugerontix. He is also Emeritus Professor of Experimental Therapeutics in the William Harvey Research Institute, Queen Mary University of London, and Visiting Professor at Sussex Drug Discovery Centre, University of Sussex. Roger’s research career spans more than 40 years combining laboratory and clinical investigations. His focus has been cardiovascular disease, but often intersecting with endocrinology, diabetes and neuroscience. His interest in endothelial function started in 1991 when Nobel Laureate Sir John Vane recruited him to lead endothelin research at the William Harvey Research Institute. Roger is a GPhC registered pharmacist, with MSc in pharmacology and PhD in Chemical Pathology (an ideal background for hunting new biomarkers of disease throughout his career). He has played a leading role in discovering the health benefits of polyphenols, and is author of "The Wine Diet"; a bestselling book about wine and the optimal diet for increasing healthspan.

James Peyer is the Chief Executive Officer and Co-Founder of Cambrian Bio. He also holds multiple board and executive roles across Cambrian’s pipeline. He has spent his entire life dedicated to the mission of finding ways of preventing people from getting diseases like cancer and Alzheimer’s instead of waiting for people to get sick. Dr. Peyer was previously Founder and Managing Partner at Apollo Ventures, the first global longevity-focused venture capital firm, investing across the US and Europe. Prior to Apollo, Dr. Peyer was a biotech R& D specialist at the New York office of McKinsey & Company, serving major pharmaceutical clients. He earned his PhD in stem cell biology at University of Texas Southwestern Medical Center as a National Science Foundation Fellow and received his BA with special honors from the University of Chicago.